Cardium Appoints CMO to Lead Generx™ Development Program
News Jan 24, 2006
Cardium Therapeutics, Inc. has announced the appointment of Randall W. Moreadith, M.D., Ph.D. as Executive Vice President and Chief Medical Officer.
"We are very pleased to welcome Dr. Randall Moreadith to Cardium's executive management team," said Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics.
"He assumes a key leadership position in our company to accelerate the late-stage clinical development of our lead product candidate, Generx, and to seek out promising corporate development opportunities."
Dr. Moreadith added, "I am very excited about joining Cardium's talented team and look forward to contributing to its future growth and success."
Before joining Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. Previously, he was co-founder, President and Chief Operating Officer of ThromboGenics Ltd., and served as Principal Medical Officer of Quintiles, Inc. where he co-founded Quintiles' Cardiovascular Therapeutics Group.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.